Skip to main content
Top
Published in: Journal of the International AIDS Society 1/2011

Open Access 01-12-2011 | Short report

Viral load testing in a resource-limited setting: quality control is critical

Authors: Jane Greig, Philipp du Cros, Derryck Klarkowski, Clair Mills, Steffen Jørgensen, P Richard Harrigan, Daniel P O’Brien

Published in: Journal of the International AIDS Society | Issue 1/2011

Login to get access

Abstract

Background

World Health Organization guidelines now recommend routine use of viral load testing, where available, for patients receiving antiretroviral treatment (ART). However, its use has not been routinely implemented in many resource-limited settings due to cost, availability and accessibility. Viral load testing is complex, making its application in resource-limited settings challenging. We describe the issues encountered by Médecins Sans Frontières (MSF) when using routine viral load testing in a large HIV programme in sub-Saharan Africa.

Methods

Between October 2005 and August 2006, more than 1200 patients on ART had viral load tests at baseline and at three-month intervals performed by a local reference laboratory that was quality assured by an experienced international institution. Concerns with reliability of results halted testing. The quality control measures instituted with a second laboratory and outcomes of these were documented.

Results

In 2005 and 2006, only 178 of 334 (53%) previously ART-naïve patients tested after six to 12 months of treatment had viral loads of less than 1000 copies/mL. Similar MSF programmes elsewhere demonstrated virological suppression rates of more than 85%, and duplicate testing showed unacceptable discordance. Laboratory problems encountered included: disregarded quality control; time delays; requirement for retesting; and duplicate sample variations. Potentially harmful clinical outcomes of inaccurate viral load results include: unnecessary ART regimen changes; unnecessary enhanced adherence counselling after "false failures"; and undetected virological failure.

Conclusions

Viral load testing performed without rigorous quality control carries the risk of erroneous and potentially damaging results. Viral load testing should be utilized only if robust quality assurance has been implemented. Our experience in this and other settings led to the development of a guide for assessing the suitability of a laboratory for viral load testing that can be used to help achieve reliable results.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kantor R, Diero L, Delong A, Kamle L, Muyonga S, Mambo F, Walumbe E, Emonyi W, Chan P, Carter EJ, Hogan J, Buziba N: Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009, 49:454–462.PubMedCrossRef Kantor R, Diero L, Delong A, Kamle L, Muyonga S, Mambo F, Walumbe E, Emonyi W, Chan P, Carter EJ, Hogan J, Buziba N: Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009, 49:454–462.PubMedCrossRef
2.
go back to reference van Oosterhout JJ, Brown L, Weigel R, Kumwenda JJ, Mzinganjira D, Saukila N, Mhango B, Hartung T, Phiri S, Hosseinipour MC: Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health 2009, 14:856–861.PubMedCrossRef van Oosterhout JJ, Brown L, Weigel R, Kumwenda JJ, Mzinganjira D, Saukila N, Mhango B, Hartung T, Phiri S, Hosseinipour MC: Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health 2009, 14:856–861.PubMedCrossRef
3.
go back to reference DART Trial Team: Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010, 375:123–131.CrossRef DART Trial Team: Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010, 375:123–131.CrossRef
4.
go back to reference Coutinho A, Mermin J, Ekwaru J, Were W, Bunnell R, Kaharuza F, Alexander L, Solberg P, Tappero J, Moore D: Utility of Routine Viral Load, CD4 Cell Count, and Clinical Monitoring among HIV-Infected Adults in Uganda: A Randomized Trial [abstract]. [http://www.retroconference.org/2008/Abstracts/30881.htm] 15th Conference on Retroviruses and Opportunistic Infections; February 2008; Boston, US Coutinho A, Mermin J, Ekwaru J, Were W, Bunnell R, Kaharuza F, Alexander L, Solberg P, Tappero J, Moore D: Utility of Routine Viral Load, CD4 Cell Count, and Clinical Monitoring among HIV-Infected Adults in Uganda: A Randomized Trial [abstract]. [http://​www.​retroconference.​org/​2008/​Abstracts/​30881.​htm] 15th Conference on Retroviruses and Opportunistic Infections; February 2008; Boston, US
5.
go back to reference The ART-LINC of IeDEA Study Group: Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 2009, 23:1867–1874.CrossRef The ART-LINC of IeDEA Study Group: Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 2009, 23:1867–1874.CrossRef
6.
go back to reference Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, Goemaere E, Garcia de la Vega F, Perrin L, Rodriguez W: HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007, 44:128–134.PubMedCrossRef Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, Goemaere E, Garcia de la Vega F, Perrin L, Rodriguez W: HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007, 44:128–134.PubMedCrossRef
7.
go back to reference WHO: Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Geneva: World Health Organization; 2009. WHO: Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Geneva: World Health Organization; 2009.
8.
go back to reference Petti CA, Polage CR, Quinn TC, Ronald AR, Sande MA: Laboratory medicine in Africa: a barrier to effective health care. Clin Infect Dis 2006, 42:377–382.PubMedCrossRef Petti CA, Polage CR, Quinn TC, Ronald AR, Sande MA: Laboratory medicine in Africa: a barrier to effective health care. Clin Infect Dis 2006, 42:377–382.PubMedCrossRef
9.
go back to reference Fiscus SA, Cheng B, Crowe SM, Demeter L, Jennings C, Miller V, Respess R, Stevens W, the Forum for Collaborative HIV Research Alternative Viral Load Assay Working Group: HIV-1 viral load assays for resource-limited settings. PLoS Medicine 2006, 3:1743–1750. Fiscus SA, Cheng B, Crowe SM, Demeter L, Jennings C, Miller V, Respess R, Stevens W, the Forum for Collaborative HIV Research Alternative Viral Load Assay Working Group: HIV-1 viral load assays for resource-limited settings. PLoS Medicine 2006, 3:1743–1750.
10.
go back to reference Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Int J Nurs Stud 2010, 47:931–936.CrossRef Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Int J Nurs Stud 2010, 47:931–936.CrossRef
11.
go back to reference WHO: Antiretroviral therapy for adults and adolescents in resource-limited settings: towards universal access. Geneva: World Health Organization; 2006. WHO: Antiretroviral therapy for adults and adolescents in resource-limited settings: towards universal access. Geneva: World Health Organization; 2006.
12.
go back to reference Elema R, Mills C, Yun O, Lokuge K, Ssonko C, Nyirongo N, Mtonga V, Zulu H, Tu D, Verputten M, O'Brien DP: Outcomes of a remote, decentralized health center-based HIV/AIDS antiretroviral program in Zambia, 2003 to 2007. J Int Assoc Physicians AIDS Care (Chic Ill) 2009, 8:60–67.CrossRef Elema R, Mills C, Yun O, Lokuge K, Ssonko C, Nyirongo N, Mtonga V, Zulu H, Tu D, Verputten M, O'Brien DP: Outcomes of a remote, decentralized health center-based HIV/AIDS antiretroviral program in Zambia, 2003 to 2007. J Int Assoc Physicians AIDS Care (Chic Ill) 2009, 8:60–67.CrossRef
13.
go back to reference Ferradini L, Laureillard D, Prak N, Ngeth C, Fernandez M, Pinoges L, Puertas G, Taburet AM, Ly N, Rouzioux C, Balkan S, Quillet C, Delfraissy J-F: Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS 2007, 21:2293–2301.PubMedCrossRef Ferradini L, Laureillard D, Prak N, Ngeth C, Fernandez M, Pinoges L, Puertas G, Taburet AM, Ly N, Rouzioux C, Balkan S, Quillet C, Delfraissy J-F: Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS 2007, 21:2293–2301.PubMedCrossRef
14.
go back to reference Barth RE, Schim van der Loeff MF, Schuurman R, Hoepelman AIM, Wensing AMJ: Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010, 10:155–166.PubMedCrossRef Barth RE, Schim van der Loeff MF, Schuurman R, Hoepelman AIM, Wensing AMJ: Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010, 10:155–166.PubMedCrossRef
15.
go back to reference Galli R, Merrick L, Friesenhahn M, Ziermann R: Comprehensive comparison of the VERSANT ® HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 MONITOR ® 1.5 assays on 1000 clinical specimens. J Clin Virol 2005, 34:245–252.PubMedCrossRef Galli R, Merrick L, Friesenhahn M, Ziermann R: Comprehensive comparison of the VERSANT ® HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 MONITOR ® 1.5 assays on 1000 clinical specimens. J Clin Virol 2005, 34:245–252.PubMedCrossRef
16.
go back to reference Berger A, Scherzed L, Stürmer M, Preiser W, Doerr HW, Rabenau HF: Comparative evaluation of the Cobas Amplicor HIV-1 Monitor™ Ultrasensitive Test, the new Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor™ Ultrasensitive Test and the Versant HIV RNA 3.0 assays for quantitation of HIV-1 RNA in plasma samples. J Clin Virol 2005, 33:43–51.PubMedCrossRef Berger A, Scherzed L, Stürmer M, Preiser W, Doerr HW, Rabenau HF: Comparative evaluation of the Cobas Amplicor HIV-1 Monitor™ Ultrasensitive Test, the new Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor™ Ultrasensitive Test and the Versant HIV RNA 3.0 assays for quantitation of HIV-1 RNA in plasma samples. J Clin Virol 2005, 33:43–51.PubMedCrossRef
17.
go back to reference Elbeik T, Alvord WG, Trichavaroj R, de Souza M, Dewar R, Brown A, Chernoff D, Michael NL, Nassos P, Hadley K, Ng VL: Comparative analysis of HIV-1 viral load assays on subtype quantification: Bayer Versant HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 Monitor version 1.5. JAIDS 2002, 29:330–339.PubMed Elbeik T, Alvord WG, Trichavaroj R, de Souza M, Dewar R, Brown A, Chernoff D, Michael NL, Nassos P, Hadley K, Ng VL: Comparative analysis of HIV-1 viral load assays on subtype quantification: Bayer Versant HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 Monitor version 1.5. JAIDS 2002, 29:330–339.PubMed
18.
go back to reference Bates I, Maitland K: Are laboratory services coming of age in sub-Saharan Africa? Clin Infect Dis 2006, 42:383–384.PubMedCrossRef Bates I, Maitland K: Are laboratory services coming of age in sub-Saharan Africa? Clin Infect Dis 2006, 42:383–384.PubMedCrossRef
20.
go back to reference Batz HG, Guillerm M, Gonsalves G: Scaling up antiretroviral treatment in resource-poor settings [Correspondence]. Lancet 2006, 368:445.PubMedCrossRef Batz HG, Guillerm M, Gonsalves G: Scaling up antiretroviral treatment in resource-poor settings [Correspondence]. Lancet 2006, 368:445.PubMedCrossRef
21.
go back to reference Phillips A, van Oosterhout J: DART points the way for HIV treatment programmes. Lancet 2010, 375:96–98.PubMedCrossRef Phillips A, van Oosterhout J: DART points the way for HIV treatment programmes. Lancet 2010, 375:96–98.PubMedCrossRef
Metadata
Title
Viral load testing in a resource-limited setting: quality control is critical
Authors
Jane Greig
Philipp du Cros
Derryck Klarkowski
Clair Mills
Steffen Jørgensen
P Richard Harrigan
Daniel P O’Brien
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of the International AIDS Society / Issue 1/2011
Electronic ISSN: 1758-2652
DOI
https://doi.org/10.1186/1758-2652-14-23

Other articles of this Issue 1/2011

Journal of the International AIDS Society 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.